The US Preventive Services Task Force recommends use of preexposure prophylaxis (PrEP) for individuals at risk of acquiring HIV.1 The Centers for Disease Control and Prevention estimated that 1.1 million US individuals might benefit from PrEP,2 but only 7% of those used it in 2016.3 Clinicians have been slow to prescribe PrEP, citing concerns regarding its effectiveness outside a clinical trial setting, unintended consequences, and ambiguity surrounding which type of clinician is best suited to prescribe PrEP.4 Using a commercial insurance database, this study examined trends in the number of persons prescribed PrEP, prescriptions for PrEP, and specialty of prescribing clinicians.
Song HJ, Squires P, Wilson D, Lo-Ciganic W, Cook RL, Park H. Trends in HIV Preexposure Prophylaxis Prescribing in the United States, 2012-2018. JAMA. 2020;324(4):395–397. doi:10.1001/jama.2020.7312
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: